Meet our speakers
-
Sally C Benton
Consultant Biochemist and Southern BCSP Hub Director
Sally Benton is Consultant Clinical Scientist in Biochemistry and Clinical Lead for Clinical and Specialist Biochemistry Services at Berkshire and Surrey Pathology Services. She is also Director of the Bowel Cancer Screening South England Hub at the Royal Surrey County Hospital, Guildford.
Sally has been working in Guildford since 2014. Her job is split between routine and specialist biochemistry services and the Bowel Cancer screening Hub. At the Bowel Cancer Hub she leads a team of research scientists who carry out research to further understand analytical aspects and clinical applications of the faecal immunochemical test for haemoglobin (FIT) and other biomarkers supporting early diagnosis of colorectal cancer. Sally and her team publish frequently in the field of FIT and early diagnosis of colorectal cancer, Sally was on the BSG/ ACP guideline group representing biochemistry. She co-chairs the World Endoscopy Organisation expert working group on FIT for Screening and is Chair of an International Federation of Clinical Chemistry working group to standardise and harmonise FIT testing.
-
Dr Natalie Hunt
Consultant Clinical Biochemist
Natalie is a Consultant Clinical Biochemist at East Lancashire Hospitals NHS Trust . She was involved in setting up FIT on the OC sensor and Pledia in Lancashire and South Cumbria from 2018 onwards. Lancashire and South Cumbria cancer alliance have a dual FIT approach to testing and Natalie will be presenting some of the latest data on how dual FIT adds extra risk information for patients on lower GI referral pathways.
-
Lucy Kirkham
Blood Sciences Operational Manager
Lucy has worked in the NHS as a Biomedical Scientist for over 15 years, training initially in Haematology and Transfusion, then moving to Biochemistry before specialising as Blood Sciences. Lucy is currently Blood Sciences Operational Manager at the Countess of Chester Hospital. Having been involved in FIT since implementation of the test into the repertoire in 2020, she has worked closely with Cheshire and Merseyside Cancer Alliance to make FIT testing sustainable within the region. The work from the CMCA and trusts within the region was recognise though nomination and being a finalist in 2024, for the HSJ Awards in the category 'Provider Collaboration of the Year'.
-
Gemma Hunter
Trainee Clinical Scientist
Gemma is currently a third year Trainee Clinical Scientist on the Scientist Training Programme (STP) specialising in Clinical Biochemistry at East Lancashire Hospitals NHS Trust. Gemma is completing a part time MSc in Clinical Science (Blood Sciences) in which she has undertaken a project investigating the measurement of faecal calprotectin on the OC-Sensor Pledia and a clinical audit evaluating the appropriateness of faecal calprotectin requesting in primary care.
-
Dr Rebecca Smith
Inflammatory Bowel Disease Research Fellow
Rebecca is currently working as a Research Fellow with Dr Ahmad’s Exeter IBD Research Group. Her research focuses on early IBD diagnosis.
-
Christina Miracle Huguet
Bowel Cancer Screening Programme Manager of Tarragona province, Spain
Christina is part of the Translational, Epidemiological and Clinical Oncology research group, forming part of the Institut d'Investigació Sanitària Pere Virgili (IISPV). Cristina is also the manager of the colorectal cancer screening program of Tarragona province.
Poster Presenters:
Southern Hub Bowel Cancer Screening Research Team
The Southern Hub Bowel Cancer Screening research team, are based at the Southern Hub which is on the Research Park adjacent to the Royal Surrey Hospital in Guildford and are part of the Berkshire and Surrey Pathology Services network. The team, lead by Sally Benton, includes 3 Research Scientists Carolyn Piggott (Lead research scientist), Shane O’Driscoll and Cerin John, all of whom are state registered BMS’s and one Research Assistant, Ryan Smith.
The research team are international leaders in the analytical aspects of the FIT test including both laboratory and point of care FIT methods. The team also lead and support many clinical studies evaluating the clinical utility of FIT and other biomarkers for colorectal cancer with local, national and international collaborations and have in excess of 60 peer-reviewed publications in the field.
The group have contributed extensively towards the work of the IFCC FIT Working Group which includes the investigations for faecal haemoglobin harmonisation, suitability of EQA programmes and availability of 3rd party QC, and are now embarking on similar work for calprotectin.
Mast extends its thanks to all the speakers who have volunteered their time to present at Faec Meet 2025